Mentax has been approved for the treatment of tinea corporis (ringworm) and tinea cruris (groin fungus).

Tinea pedis, tinea corporis, and tinea cruris account for the vast majority of all skin fungal infections. Most skin fungus treatments available in the United States are fungistatic, which only arrest fungus growth. In contrast, in vitro studies demonstrate that Mentax is a potent fungicidal compound rather than only being fungistatic.

Clinicians at several major medical conferences have reported that Mentax, when dosed just once per day, is highly effective in reducing the clinical signs and symptoms of skin fungus with only a very low incidence of side effects. The drug has been evaluated in multi-center, vehicle-controlled, parallel, randomized, double-blind efficacy trials in over 1,300 subjects. Mentax achieved highly significant statistical results in these trials, eliminating fungi from tinea lesions in 90 percent of subjects.